Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study

Chi-Fai Ng, Peter K F Chiu, Chi-Hang Yee, Becky S Y Lau, Steven C H Leung, Jeremy Y C Teoh, Chi-Fai Ng, Peter K F Chiu, Chi-Hang Yee, Becky S Y Lau, Steven C H Leung, Jeremy Y C Teoh

Abstract

Androgen deprivation therapy (ADT) is the standard treatment for advanced prostate cancer, but its effect on cardiovascular and metabolic function in Asian patients is still inconclusive. We prospectively assess the effects of ADT on 36 patients with advanced prostate cancer, with reference to another 24 prostate cancer patients not requiring ADT, for 2 years. Patients' anthropometric, metabolic and vascular parameters were assessed every six-monthly. The baseline parameters of the two groups were comparable. There was a significant negative effect of the usage of ADT on the changes in BMI (p = 0.020), waist to hip ratio (p = 0.005), body fat percentage (p = 0.012), and high-density-lipoprotein (p = 0.012). ADT-patients were 4.9 times more likely to have metabolic syndrome at 24 months. (CI 0.889-27.193, p = 0.068). The Framingham risk score (p = 0.018) and pulse-wave-velocity (p = 0.024) for ADT-group were also significantly higher than controls, which signified increase in cardiovascular risk. Although there was no statistically significant difference in ischemic cardiovascular events between two groups, a trend for more events in ADT-group was observed. Therefore, Asian patients have increased cardiovascular and metabolic risks after being treated with ADT for two years. Appropriate counselling and monitoring of associated complications with ADT are essential.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flowchart of patient follow-up information.
Figure 2
Figure 2
Changes in (a) Framingham risk score and (b) pulse-wave velocity over time for the two groups. Study ADT group, Control control group.

References

    1. Shore ND, et al. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines. Prostate. 2020;80:527–544. doi: 10.1002/pros.23967.
    1. Damodaran S, Kyriakopoulos CE, Jarrard DF. Newly diagnosed metastatic prostate cancer: has the paradigm changed? Urol. Clin. N. Am. 2017;44:611–621. doi: 10.1016/j.ucl.2017.07.008.
    1. Smith MR, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 2002;87:599–603. doi: 10.1210/jcem.87.2.8299.
    1. Smith JC, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab. 2001;86:4261–4267. doi: 10.1210/jcem.86.9.7851.
    1. Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J. Urol. 2004;171:2285–2290. doi: 10.1097/01.ju.0000127740.96006.1a.
    1. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 2006;24:4448–4456. doi: 10.1200/JCO.2006.06.2497.
    1. Nguyen PL, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359–2366. doi: 10.1001/jama.2011.1745.
    1. Levine GN, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation. 2010;121:833–840. doi: 10.1161/CIRCULATIONAHA.109.192695.
    1. Hu JR, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler. Thromb. Vasc. Biol. 2020;40:e55–e64.
    1. Akaza H. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology. 2010;85:110–120. doi: 10.1159/000274486.
    1. Huang G, et al. Androgen deprivation therapy and cardiovascular risk in Chinese patients with nonmetastatic carcinoma of prostate. J Oncol. 2014 doi: 10.1155/2014/529468.
    1. Teoh JY, et al. Risk of acute myocardial infarction after androgen- deprivation therapy for prostate cancer in a Chinese population. BJU Int. 2015;116:382–387. doi: 10.1111/bju.12967.
    1. Wang LH, et al. No Increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men. Andrology. 2016;4:128–132. doi: 10.1111/andr.12141.
    1. Shim M, et al. The use of gonadotropin-releasing hormone agonist does not affect the development of cardiovascular disease in prostate cancer patients: a nationwide population-based cohort study. J. Korean Med. Sci. 2020;35:e47. doi: 10.3346/jkms.2020.35.e47.
    1. Seong JM, et al. Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an Asian population-based observational study. J. Cancer. 2011;11:4015–4022. doi: 10.7150/jca.38237.
    1. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br. J. Nutr. 1974;32:77–97. doi: 10.1079/BJN19740060.
    1. Munakata M. Brachial-ankle pulse wave velocity in the measurement of arterial stiffness: recent evidence and clinical applications. Curr. Hypertens. Rev. 2014;10:49–57. doi: 10.2174/157340211001141111160957.
    1. Sugarwara J, et al. Brachial-ankle pulse wave velocity: an index of central arterial stiffness. J. Hum. Hypertens. 2005;19:401–406. doi: 10.1038/sj.jhh.1001838.
    1. D'Agostino RB, Sr, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753. doi: 10.1161/CIRCULATIONAHA.107.699579.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high Blood cholesterol in adults (adult treatment panel III). JAMA. 285, 2486–2497 (2001).
    1. Levine GN, et al. American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121:833–840. doi: 10.1161/CIRCULATIONAHA.109.192695.
    1. Carneiro A, et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J. Urol. 2015;33:1281–1289. doi: 10.1007/s00345-014-1439-6.
    1. Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther. Adv. Urol. 2016;8:118–129. doi: 10.1177/1756287215617872.
    1. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin. Sci. 2003;104:195–201. doi: 10.1042/cs1040195.
    1. Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J. Androl. 2009;30:410–415. doi: 10.2164/jandrol.108.006924.
    1. Oka R, et al. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. Int. J. Clin. Oncol. 2016;21:389–396. doi: 10.1007/s10147-015-0891-7.
    1. Albertsen PC, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur. Urol. 2014;65:565–573. doi: 10.1016/j.eururo.2013.10.032.
    1. Ng CF, et al. The real-life evaluation of the effect of androgen deprivation therapy (ADT) in prostate cancer patients in Asia study: the initial report of the usage of ADT pattern in Asia. Int. J. Urol. 2019;26(S2):22.
    1. Bhatia N, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133:537–541. doi: 10.1161/CIRCULATIONAHA.115.012519.
    1. Shore ND, et al. Hero study investigators oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N. Engl. J. Med. 2020;382:2187–2196. doi: 10.1056/NEJMoa2004325.
    1. Abida W, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5:471–478. doi: 10.1001/jamaoncol.2018.5801.
    1. Donato MD, et al. Nerve growth factor induces proliferation and aggressiveness in prostate cancer cells. Cancers. 2019;11:784. doi: 10.3390/cancers11060784.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit